Takeda Pharmaceutical Company Limited

Tokyo Stock Exchange:4502.T

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

Location

Japan

Market Cap

USD 46.97 B

Share Price

USD 30.06

Avg Daily Volume

5,104,727

Change (1 day)

0.25%

Change (1 year)

16.05%

Change (YTD)

12.86%

Takeda Pharmaceutical Company Limited Enterprise Value to EBITDA (EV/EBITDA) on June 26, 2025: 9.72

Takeda Pharmaceutical Company Limited Enterprise Value to EBITDA (EV/EBITDA) is 9.72 on June 26, 2025, a -19.41% change year over year. EV/EBITDA ratio compares the enterprise value to the EBITDA; lower suggests more favorable company valuation.

Takeda Pharmaceutical Company Limited 52-week low Enterprise Value to EBITDA (EV/EBITDA) is 13.43 on June 26, 2025, which is 38.23% above the current Enterprise Value to EBITDA (EV/EBITDA).
Takeda Pharmaceutical Company Limited 52-week low Enterprise Value to EBITDA (EV/EBITDA) is 9.10 on June 26, 2025, which is -6.36% below the current Enterprise Value to EBITDA (EV/EBITDA).
Takeda Pharmaceutical Company Limited average Enterprise Value to EBITDA (EV/EBITDA) for the last 52 weeks is 11.88.

Daily

From:

To:

Zoom:

Key data

Date	Enterprise Value to EBITDA (EV/EBITDA)	Free Cash Flow Yield	Dividend Yield	Market Capitalization

Tokyo Stock Exchange: 4502.T

Takeda Pharmaceutical Company Limited

CEO	Mr. Christophe Weber
IPO Date	Jan. 4, 2000
Location	Japan
Headquarters	1-1, Nihonbashi-Honcho 2-chome
Employees	49,281
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals

Description

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.